Welcome to our dedicated page for Cue Biopharma news (Ticker: CUE), a resource for investors and traders seeking the latest updates and insights on Cue Biopharma stock.
Cue Biopharma, Inc. (Nasdaq: CUE) is a clinical-stage biopharmaceutical company headquartered in Boston, Massachusetts and focused on developing injectable biologics that selectively engage disease-specific T cells. News about Cue Biopharma often centers on its Immuno-STAT platform, clinical data from its CUE-100 series programs, and progress in autoimmune disease and oncology.
Investors and followers of CUE stock can use this page to review company press releases and third-party coverage related to Cue Biopharma’s pipeline. Typical updates include clinical trial readouts for CUE-101 in HPV16+ head and neck cancer and CUE-102 in WT1-expressing tumors, as well as developments around CUE-401, the company’s lead autoimmune asset designed to promote regulatory T cell–mediated tolerance.
News flow also highlights Cue Biopharma’s strategic collaborations and corporate milestones. Examples include agreements with Boehringer Ingelheim for CUE-501, a differentiated B cell depletion therapy for autoimmune and inflammatory diseases, and a collaboration and license agreement with ImmunoScape to advance a Seed-and-Boost cell therapy approach for solid tumors using the CUE-100 series. Financial updates, such as quarterly results, collaboration revenue disclosures and public equity offerings under the company’s shelf registration statement, are also common topics.
By following this CUE news feed, readers can track regulatory interactions, investigator-sponsored trials, leadership transitions, licensing deals and financing activities that may influence Cue Biopharma’s development trajectory. Bookmark this page to quickly access the latest headlines and historical announcements related to Cue Biopharma and its Immuno-STAT-based biologics.
Cue Biopharma (NASDAQ: CUE) announced a private placement expected to raise approximately $30 million in gross proceeds via pre-funded warrants and accompanying warrants. The PIPE is expected to close on or about May 4, 2026, subject to customary conditions and stockholder approval.
Proceeds are intended to advance the clinical pipeline, including acquiring and developing Ascendant-221, and for working capital and general corporate purposes. Newbridge Securities is placement agent; resale registration will be filed with the SEC.
Cue Biopharma (Nasdaq: CUE) entered an exclusive license agreement for Ascendant-221, a Phase 2 anti-IgE antibody, gaining global rights excluding mainland China, Hong Kong, Macau and Taiwan.
Deal consideration includes a $15 million upfront fee, up to $676.5 million in milestone payments and tiered royalties. Ascendant-221 Phase 2 results from a China study are expected in 2H 2026; Cue plans a global Phase 2b in food allergy after data review.
Cue Biopharma (Nasdaq: CUE) appointed Shao-Lee Lin, M.D., Ph.D., as CEO, President and board director effective April 30, 2026.
Dr. Lin brings 25+ years of leadership, previously founded and led a Nasdaq company, raised over $1 billion, and guided a $2+ billion IPO valuation. Cue highlighted advancement of CUE-401 to Phase 1 and an added ongoing Phase 2 program targeting allergic disease with a potential near-term inflection in 2H2026.
Cue Biopharma (Nasdaq: CUE) will implement a 1-for-30 reverse stock split effective 5:00 p.m. ET on April 23, 2026, with split-adjusted trading expected when markets open April 24, 2026 under ticker CUE and new CUSIP 22978P205.
The split reduces outstanding shares from ~97.7 million to ~3.3 million and is intended to help the company regain compliance with Nasdaq Capital Market minimum bid price requirements; fractional shares will be paid in cash and equity awards will be adjusted proportionately.
Cue Biopharma (Nasdaq: CUE) will present new preclinical data on lead candidate CUE-401 at IMMUNOLOGY2026 in Boston, April 15-19, 2026. The poster describes a bifunctional TGF-beta/IL-2 fusion that promotes antigen-specific FOXP3+ iTreg expansion, supporting potential to restore immune homeostasis.
Cue Biopharma (Nasdaq: CUE) will receive a $7.5 million preclinical milestone payment from its collaboration and license agreement with Boehringer Ingelheim after selection and approval of the first compound for lead optimization. The company expects the payment in May 2026. The multi-year collaboration could yield up to $337.5 million in additional milestone payments plus royalties and allows expansion into B cell-targeting bispecifics. Cue is advancing its lead autoimmune asset, CUE-401, toward the clinic while Boehringer Ingelheim will further develop CUE-501 under the agreement.
Cue Biopharma (Nasdaq: CUE) appointed Lucinda Warren as interim president and chief executive officer, effective March 27, 2026, after Usman Azam stepped down effective March 26, 2026. The board credited Ms. Warren with recent deal execution, including recovery of CUE-401 rights and collaborations with Boehringer Ingelheim and ImmunoScape.
Ms. Warren said she will focus on advancing CUE-401 into the clinic by the second half of 2026; she has 30+ years of global pharma and biotech experience and prior business development leadership at Johnson & Johnson.
Cue Biopharma (Nasdaq: CUE) will host a virtual R&D Day on April 7, 2026 at 10:00 AM EDT to present research on its lead asset, CUE-401, aimed at regulating proinflammatory mechanisms and promoting Treg differentiation for autoimmune and inflammatory diseases.
Key Opinion Leaders Richard DiPaolo, PhD, and Jonathan Kay, MD, will join company management for presentations, followed by a live Q&A. A live and archived webcast will be available on the company website and will be archived for 30 days.
Cue Biopharma (Nasdaq: CUE) reported Q4 and full-year 2025 results on March 16, 2026, highlighting a strategic collaboration with ImmunoScape, progress on lead autoimmune candidate CUE-401, and financing actions.
Key metrics: Q4 collaboration revenue of $21.9M, full-year collaboration revenue of $27.5M, cash and equivalents of $27.1M at year-end, net loss for 2025 of $26.6M, and net proceeds of $10.2M from a public offering. The company received $9.5M of a $15M upfront payment and obtained a 40% equity stake in ImmunoScape.
Cue Biopharma (Nasdaq: CUE) will present new in vitro data for lead asset CUE-401 at the World Immune Regulation Meeting (WIRM) in Davos, March 11–14, 2026.
The poster (Session P5) on March 12, 2026 highlights CUE-401’s TGF-β/IL-2 bifunctional design, reporting TGF-β–dependent suppression of proinflammatory cells, prevention of B cell plasma differentiation, NK cell modulation, and expansion of regulatory T cells.